Hair Dye Use in Multiple Myeloma Patients
Patients with multiple myeloma can safely dye their hair, as there is no evidence that hair dye use after diagnosis affects disease progression, treatment outcomes, or survival.
Evidence Base
The provided clinical practice guidelines for multiple myeloma from major organizations (ASCO, NCCN, EHA-EMN) 1, 2, 3, 4, 3, 1 do not include any restrictions or warnings regarding hair dye use during treatment. These comprehensive guidelines address numerous supportive care issues and treatment-related precautions but make no mention of avoiding hair coloring products.
Research on Hair Dye and Myeloma Risk
While the question concerns patients already diagnosed with myeloma, it's worth noting the research on hair dye use and myeloma development:
- No increased risk found: Multiple large epidemiologic studies found no association between hair dye use and multiple myeloma risk 5, 6, 7
- One exception: A single study found increased risk only in women who used black permanent hair dyes for ≥20 years (based on only 2 cases) 8
- Overall consensus: A systematic review concluded evidence was inadequate to establish causality 9
Practical Considerations During Treatment
While hair dyeing is not contraindicated, consider these treatment-related factors:
Chemotherapy effects on hair:
- Some myeloma regimens may cause hair thinning or texture changes
- Hair may be more fragile during active treatment
- Scalp sensitivity may be increased with certain therapies
Infection risk management:
- Patients on immunomodulatory drugs or proteasome inhibitors have increased infection susceptibility 3, 10
- Ensure any scalp irritation or breaks in skin are avoided during dye application
- Professional application in a clean salon environment is preferable to minimize infection risk
Timing considerations:
- Avoid dyeing hair during periods of severe neutropenia (if present)
- Wait until any scalp lesions or irritation from myeloma-related skin involvement have healed
Bottom Line
There is no medical contraindication to hair dyeing in multiple myeloma patients. The decision should be based on patient preference, hair condition, and general infection prevention practices rather than concerns about the myeloma itself or treatment efficacy.